Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD
NCT04269850 · St. Petersburg State Pavlov Medical University · PHASE1/PHASE2 · terminated · last registry update 2024-12-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Poor recruitment” | – | Registry record, St. Petersburg State Pavlov Medical University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-24Results posted on the registry: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT05764161)
- 2025-11-18Also stopped (withdrawn): Oncology Institute of Southern Switzerland, Ruxolitinib 20 MG (NCT03274778)
- 2025-11-14Results posted on the registry: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT05755438)
- 2025-10-29Phase 3 first posted: Eli Lilly and Company, Baricitinib + Placebo (NCT07222137)
- 2025-10-29Phase 3 first posted: Eli Lilly and Company, Baricitinib + Placebo (NCT07222332)
- 2025-10-01Results posted on the registry: Eli Lilly and Company, Baricitinib + Placebo (NCT03570749)
- 2025-08-21Phase 3 first posted: Sun Pharmaceutical Industries, Inc., Deuruxolitinib + Placebo (NCT07133308)
- 2025-07-02Results posted on the registry: LEO Pharma, Delgocitinib + Cream vehicle (NCT05355818)
- 2025-06-16Phase 3 first posted: AbbVie, Upadacitinib + Upadacitinib Placebo (NCT07023302)
- 2025-05-18Phase 3 first posted: Priovant Therapeutics, Inc., Oral Brepocitinib + Oral Placebo (NCT06978725)
- 2025-05-06Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06958211)
- 2025-05-06Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06959225)
- 2025-04-17Results posted on the registry: Novartis Pharmaceuticals, INC424 (NCT03774082)
- 2025-04-15Phase 3 first posted: Douglas D. Fraser, Pirfenidone + Placebo for pirfenidone (NCT06928272)
- 2025-03-20Phase 3 first posted: Hangzhou Highlightll Pharmaceutical Co., Ltd, TLL-018 (NCT06887127)
- 2025-03-12Results posted on the registry: AbbVie, Ruxolitinib + Navitoclax (NCT03222609)
- 2025-03-07Phase 3 first posted: Alfasigma S.p.A., Filgotinib (NCT06865417)
- 2025-03-07Results posted on the registry: AbbVie, Upadacitinib + Corticosteroid (CS) (NCT03725202)
- 2025-02-18Phase 3 first posted: Incyte Corporation, Ruxolitinib + Vehicle Cream (NCT06832618)
- 2025-02-12Results posted on the registry: Adeline Vanderver, MD, Baricitinib (NCT03921554)
- 2025-02-04Phase 3 first posted: Pfizer, Abrocitinib (NCT06807281)
- 2025-02-04Phase 3 first posted: Pfizer, Abrocitinib (NCT06807268)
- 2025-02-03Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06804811)
- 2024-11-22Phase 3 first posted: AbbVie, Placebo + Upadacitinib (NCT06701331)
- 2024-10-29Results posted on the registry: Mayo Clinic, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter + Ruxolitinib Phosphate (NCT03120624)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision